Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Tardive Dyskinesia: later-stage trial registry
3 of 6 indexed Tardive Dyskinesia trials are currently recruiting, with more weight in Phase 3-4.
Corpus placement: #2,866 of 28,707 conditions by registered trial count.
6 US clinical trials · 3 currently recruiting · #2,866 of 28,707 conditions by registered trial count
Tardive Dyskinesia: 6 US clinical trials tracked, 3 recruiting.
Tardive Dyskinesia is the subject of 6 registered US clinical trials on ClinicalTrials.gov, 3 of them currently open to new participants. 4 are in Phase 3-4 (later-stage) and 1 in Phase 1-2 (earlier-stage). The most active sponsor is Neurocrine Biosciences, running 2 of these trials.
Enrollment posture brief
Registry condition tardive-dyskinesia
OPEN 3 | RECR 50% | LATE 4 | EARLY 1 | RANK #2866 | SPON 2
Volume-matched condition peers
Nearest open-share peer: Achalasia (50% recruiting · 8 trials)
Tardive Dyskinesia lists 3 open slots (50% of 6 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Tardive Dyskinesia on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Tardive Dyskinesia is recruiting above its size-band peers.
3 of 6 indexed trials (50%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Tardive Dyskinesia research.
Neurocrine Biosciences accounts for 2 of 6 trials (33.3%). 5 distinct sponsors appear on at least one study for this condition label.
-
Most Tardive Dyskinesia trials plan to enrol fewer than 100 people.
Median target enrolment is 50 among the 6 trials that report a genuine target (sentinel values excluded). 4 of those (66.7%) plan for fewer than 100 participants.
-
Tardive Dyskinesia research is mostly interventional.
6 interventional and 0 observational studies make up this index (100% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
6 total, page 1 of 1
Remote Monitoring and Detecting of Tardive Dyskinesia for Improving Patient Outcomes
iRxReminder
NCT06011408
A Study to Evaluate the Effectiveness of Valbenazine in Adult Participants With Tardive Dyskinesia (TD) Who Remain Symptomatic While Receiving or After Stopping a Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor
Neurocrine Biosciences
NCT07105111
Smoking Cessation With Varenicline in Schizophrenia: Antipsychotic-Induced Neurological Symptoms as Correlates
Corporal Michael J. Crescenz VA Medical Center
NCT03495024
Addressing Involuntary Movements in Tardive Dyskinesia
Auspex Pharmaceuticals
NCT02291861
Levetiracetam Treatment of Tardive Dyskinesia
Yale University
NCT00291213
NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder
Neurocrine Biosciences
NCT01393600
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 2 | 1 |
| Phase 3 | 2 |
| Phase 4 | 2 |
Top Sponsors
Named interventions
Most-linked intervention names on Tardive Dyskinesia records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Tardive Dyskinesia trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Tardive Dyskinesia page
6 registered trials, 3 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 3 Tardive Dyskinesia trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Neurocrine Biosciences sponsors the most Tardive Dyskinesia trials on record, review their full trial history before evaluating a specific study. See Neurocrine Biosciences's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Tardive Dyskinesia condition card totals 6 registered trials; most-linked intervention Placebo; top US site state Florida. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.